Biopharmaceutical Manufacturing Market

Market Overview:

The global biopharmaceutical manufacturing market size reached US$ 371.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 690.7 Billion by 2028, exhibiting a growth rate (CAGR) of 10.6% during 2023-2028.

The manufacturing of biopharmaceuticals (biopharma) is characterized by a highly complex research and development (R&D) setting, which includes the use of technologies that are harnessed by new scientific advances. The production process of biopharmaceuticals supports a wide range of production-related, highly specialized jobs. Some of these employments include packaging and filling machine operators and tenders, blending and mixing machine setters, and testers, inspectors, samplers, sorters, and chemical equipment operators. Different methods can be deployed for the production of biopharmaceuticals, which include continuous and follow-on manufacturing systems. In the continuous system, raw materials are fed continuously from one end into the process and the finished product is extracted from the other end. On the other hand, the follow-on product development mostly includes the adoption of both current and legacy bioprocessing technologies to obtain a cost-effective procedure to make drugs.

With the emergence of the industrial revolution 4.0, biopharma manufacturers have been increasingly using a digitized paradigm that involves machines to collect, process and produce data, then communicate it with other machines through the Industrial Internet of Things (IIoT). These next-generation technologies have helped industry players to increase process understanding with the provision of more data with advanced modeling techniques and analytics. Besides this, expansion in the biopharma industry has led to the emerging trend of outsourcing due to high costs, and lack of expertise in in-house manufacturing. As a result, contract manufacturing organizations (CMOs) are investing heavily to expand their existing capabilities and capacities. Most of these firms are based across developed regions. However, the advent of advanced manufacturing methods and technologies in emerging economies, like India and China, has led to a significant shift in the market. Also, the industry currently accounts for a sophisticated, specialized and highly regulated field with outsized economic contributions across the globe.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global biopharmaceutical manufacturing market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on cell culture and class.

Breakup by Cell Culture:

• Mammalian
• Microbial

At present, mammalian cell culture is the largest segment in the market.

Breakup by Class:

• Monoclonal Antibodies
• Recombinant Proteins
• Interferon
• Granulocyte Colony-Stimulating Factor (G-CSF)
• Erythropoietin
• Recombinant Human Insulin
• Vaccines
• Human Growth Hormones (HGH)

Amongst the above-mentioned categories, monoclonal antibodies dominate the market.

Regional Insights:

• North America
• Europe
• Asia

Currently, North America is the biggest market, accounting for the majority of the total market share.

Competitive Landscape:

The report has also analyzed the competitive landscape of the market, with some of the key players being F. Hoffmann-La Roche Ltd, Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Groupe Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, and Biogen Inc.

Report Coverage:

Key Questions Answered in This Report:

• How has the global biopharmaceutical industry performed so far and how will it perform in the coming years?
• What are the current and historical manufacturing capacity trends in the biopharmaceutical manufacturing industry?
• What has been the impact of COVID-19 on the global biopharmaceutical industry?
• What are the key regional markets in the industry?
• What is the breakup of the market based on the class?
• What is the breakup of the market based on the cell culture?
• What is the structure of the industry and who are the key players?